Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD

References

• Global Initiative for Obstructive Lung Disease (GOLD)Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease2011 Available from: http://www.goldcopd.org/guidelines-gold-summary-2011.html
   Google Scholar
• ViegiGPistelliFSherrillDLMaioSBaldacciSCarrozziLDefinition, epidemiology and natural history of COPDEur Respir J200730993101317978157
   PubMed Web of Science ®Google Scholar
• UK Medicines Information New Drugs OnlineGlycopyrrolate2012 Available from: http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=4793Accessed April 12, 2013
   Google Scholar
• UK Medicines Information New Drugs OnlineAclidinium bromide2012 Available from: http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=4515Accessed April 12, 2012
   Google Scholar
• TashkinDPLong-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safetyCurr Opin Pulm Med2010169710520019615
   PubMed Web of Science ®Google Scholar
• SykesDADowlingMRCharltonSJExploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptorMol Pharmacol20097654355119498041
   PubMed Web of Science ®Google Scholar
• VogelmeierCBanerjiDNVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary diseaseTher Adv Respir Dis2011516317321511677
   PubMedGoogle Scholar
• SechaudRRanardDZhang-AubersonLde la MotteSDrollmannAKaiserGPharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD)Int J Clin Pharmacol Ther20125011812822257577
   PubMed Web of Science ®Google Scholar
• global Initiative for Chronic Obstructive Lung Disease (GOLD 2008)Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease Available from: http://www.ncbi.nlm.nih.gov/pubmed/17507545
   Google Scholar
• National Institute for Health and Clinical ExcellenceChronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary careLondon, UKNational Clinical Guideline Centre2010 Available from: http://guidance.nice.org.uk/CG101/Guidance/pdf/EnglishAccessed April 13, 2013
   Google Scholar
• BuhlRBanjeriDProfile of glycopyrronium for once-daily treatment of moderate-to-severe COPDInt J Chron Obstruct Pulmon Dis2012772974123118536
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med20113641093110321428765
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med200735677578917314337
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med20083591543155418836213
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/ fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med2008177192617916806
   PubMed Web of Science ®Google Scholar
• AaronSDVandehmheenKLFergussonDTiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary diseaseAnn Intern Med200714654555517310045
   PubMed Web of Science ®Google Scholar
• CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J20021921722411866001
   PubMed Web of Science ®Google Scholar
• O’DonnellDEFlugeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEur Respir J20042383284015218994
   PubMed Web of Science ®Google Scholar
• CelliBZuwallackRWangSKestenSImprovement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumesChest20031241743174814605043
   PubMed Web of Science ®Google Scholar
• CasaburiRFactors determining constant work rate exercise tolerance in COPD and their role in dictating the minimal clinically important difference in response to interventionsCOPD2005213113617136973
   PubMedGoogle Scholar
• MaltaisFHamiltonAMarciniukDImprovements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPDChest20051281168117816162703
   PubMed Web of Science ®Google Scholar
• DonohueJFvan NoordJABatemanEDA 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterolChest2002122475512114338
   PubMed Web of Science ®Google Scholar
• NiewoehnerDERiceKCoteCPrevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trialAnn Intern Med200514331732616144890
   PubMed Web of Science ®Google Scholar
• FogartyCHattersleyHDi ScalaLDrollmannABronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patientsRespir Med201110533734221144724
   PubMed Web of Science ®Google Scholar
• VerkindreCFukuchiYFlemaleASustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patientsRespir Med20101041482148920541381
   PubMed Web of Science ®Google Scholar
• VogelmeierCVerkindreCCheungDSafety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patientsPulm Pharmacol Ther20102343844420416390
   PubMed Web of Science ®Google Scholar
• D’UrzoAFergusonGTvan NoordJAEfficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialRespir Res20111215622151296
   PubMed Web of Science ®Google Scholar
• KerwinEHebertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J2012401106111423060624
   PubMed Web of Science ®Google Scholar
• BeehMKSinghDDi ScalaLDrollmannAOnce-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trialInt J Chron Obstruct Pulmon Dis2012750351322973092
   PubMed Web of Science ®Google Scholar
• European Respiratory SocietyClinical exercise testing with reference to lung diseases: indications, standardization and interpretation strategies. ERS Task Force on Standardization of Clinical Exercise TestingEur Respir J199710266226899426113
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease Updated2010 Available from: http://www.goldcopd.org/Guidelines/guideline-2010-gold-report.html
   Google Scholar
• TashkinDCelliBDecramerMPrescribing patterns according to COPD treatment guidelines in patients enrolled in a global clinical trialProc Am Thorac Soc20063A111
   PubMedGoogle Scholar
• KarnerCCatesCJThe effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20119CD00903921901729
   PubMed Web of Science ®Google Scholar
• CazzolaMMolimardMThe scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPDPulm Pharmacol Ther20102325726720381630
   PubMed Web of Science ®Google Scholar
• RouxEMolimardMSavineauJPMarthanRMuscarinic stimulation of airway smooth muscle cellsGen Pharmacol1998313493569703200
   PubMedGoogle Scholar
• van NoordJAAumannJLJanssensEComparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEur Respir J20052621422216055868
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEEffects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPDChest200612950951716537846
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensECombining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptomsRespir Med2010104995100420303247
   PubMed Web of Science ®Google Scholar
• TashkinDPLittnerMAndrewsCPTomlinsonLRinehartMDenis-MizeKConcomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trialRespir Med200810247948718258423
   PubMed Web of Science ®Google Scholar
• TashkinDPDonohueJFMahlerDAEffect of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPDRespir Med200910351652419208459
   PubMed Web of Science ®Google Scholar
• MaltaisFBeckEWebsterDFour weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patientsEur Respir J201036S54P5557
   Google Scholar
• CazzolaMDi MarcoFSantusPThe pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPDPulm Pharmacol Ther200417353914643169
   PubMed Web of Science ®Google Scholar
• VogelmeierCKardosPHarariSGansSJStengleinSThirlwellJFormoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month studyRespir Med20081021511152018804362
   PubMed Web of Science ®Google Scholar
• MahlerDAD’UrzoABatemanEDConcurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, doubleblind comparisonThorax20126778178822544891
   PubMed Web of Science ®Google Scholar
• D’UrzoAVogelmeierCFuture of chronic obstructive disease managementExpert Rev Respir Med2012628529922788943
   PubMed Web of Science ®Google Scholar
• van NoordJABuhlRLaforceCQVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary diseaseThorax2010651086109120978028
   PubMed Web of Science ®Google Scholar
• BatemanEFergusonGTBarnesNBenefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE studyAbstract presented at the European Respiratory Society Congress 2012Vienna, AustriaSeptember 1–5, 2012
   Google Scholar
• VogelmeierCBatemanEPallanteJOnce-daily QVA149 significantly improves lung function and symptoms compared to twice-daily fluticasone/salmeterol in COPD patients: the ILLUMINATE studyAbstract presented at the European Respiratory Society CongressVienna, AustriaSeptember 1–5, 2012
   Google Scholar
• ChapmanKRFogartyCMPeckittCDelivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPDInt J Chron Obstruct Pulmon Dis2011635336321760722
   PubMed Web of Science ®Google Scholar
• PavkovRMuellerSFiebichKCharacteristics of a capsule based dry powder inhaler for the delivery of indacaterolCurr Med Res Opin2010262527253320843166
   PubMed Web of Science ®Google Scholar
• BroedersMEMolemaJVermueNAFolgeringHTPeak inspiratory flow rate and the slope of the inhalation profiles in dry powder inhalersEur Respir J20011878078311757627
   PubMed Web of Science ®Google Scholar
• WieshammerSDreyhauptJDry powder inhalers: which factors determine the frequency of handling errors?Respiration200875182517911976
   PubMed Web of Science ®Google Scholar
• TerzanoCDry powder inhalers and the risk of errorRespiration200875141518185025
   PubMed Web of Science ®Google Scholar